POLE mutations in endometrial cancer: addressing heterogeneity, clinical applicability, and methodological refinements

read with great interest the systematic review and meta-analysis by Adella et al. [1], which investigated the prognostic value and immunotherapeutic potential of POLE mutations in endometrial cancer.This topic has great clinical relevance currently, especially as molecular classification increasingly guides risk stratification and treatment de-escalation in endometrial cancer.We appreciate the comprehensive synthesis of evidence from 25 studies conducted across diverse geographical regions.We offer several constructive methodological perspectives to further strengthen the interpretation and clinical applicability of their valuable findings.